NCT02069392View on ClinicalTrials.gov

Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
BEHAVIORAL

Cognitive remediation training

DRUG

Nicotine polacrilex lozenge

Of interest are the effects of nicotine on cognitive remediation training benefits.

Trial Locations (1)

21228

Maryland Psychiatric Research Center, Baltimore

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT02069392 - Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia | Biotech Hunter | Biotech Hunter